•
HU
HUMA
Humacyte, Inc. Common Stock
yahooBIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
--
Price Chart
Market Cap
189.14M
Volume
8.87M
52W High
$4.85
52W Low
$0.91
Open
$0.00
Prev Close
$1.02
Day Range
0.00 - 0.00
About Humacyte, Inc. Common Stock
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Latest News
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
GlobeNewswire Inc.•Dec 22
Strong Earnings and Biotech Resilience Define the Midweek Momentum
GlobeNewswire Inc.•Nov 12
Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback
Benzinga•Sep 18
Humacyte Posts Q2 Revenue Miss
The Motley Fool•Aug 11
US Stocks Likely To Open Lower After 3-Day Advance: Market Is Looking 'More Balanced' And Gone From 'Above-Trend To On-Trend,' Says Expert
Benzinga•Mar 26
DEADLINE ALERT for WOLF, HUMA, XRX, and ZETA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
GlobeNewswire Inc.•Jan 21
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Benzinga•Jan 17
HUMA DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important January 17 Deadline in Securities Class Action - HUMA
GlobeNewswire Inc.•Jan 17